Myqorzo Tablet, Film Coated
Product Images NDC 82112-105

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Myqorzo (NDC 82112-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cytokinetics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Myqorzo 01)

Chemical structure of aficamten, the active ingredient in MYQORZO tablets. The diagram shows the molecular arrangement with rings, functional groups, and stereochemistry clearly depicted.*

FDA Label Image

Figure 1 (Myqorzo 02)

A forest plot chart comparing MYQORZO versus placebo across various patient subgroups based on gender, age, baseline BMI, NYHA class, left ventricular ejection fraction, baseline NT-proBNP levels, CPET modality, baseline pVO2, beta blocker use, baseline resting LVOT, baseline KCCQ clinical summary score, and sarcomeric gene mutation status. The chart displays the number of patients per group and the least squares mean difference with 95% confidence intervals, indicating the effect of MYQORZO relative to placebo for each category.*

FDA Label Image

Figure 2 (Myqorzo 03)

A line graph depicting the least squares mean change from baseline in Clinical Summary Score over 24 weeks for MYQORZO compared to placebo. The X-axis shows time in weeks, and the Y-axis measures change in score. MYQORZO demonstrates a steady increase in score over time, while placebo remains relatively stable, with error bars representing 95% confidence intervals. Sample sizes for each group at each time point are listed below the X-axis.*

FDA Label Image

Figure 3 (Myqorzo 04)

Line graph showing the least squares mean percentage change from baseline in Valsalva LVOT-G (mmHg) over 24 weeks for MYQORZO tablets and placebo. The MYQORZO group shows a marked decrease over time compared to stable levels in the placebo group. Sample sizes at each time point are provided for both groups.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

MYQORZO 5 mg film-coated tablets packaging label showing aficamten as the active ingredient. The label includes storage temperature instructions (20°C to 25°C), dispensing information, and states the product is for oral use and prescription only. The labeler is Cytokinetics Inc., South San Francisco, CA, and the package contains 30 tablets.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Label for MYQORZO (aficamten) tablets 10 mg film-coated oral tablets. The label includes dosing guidance notes, storage instructions to store at 20°C to 25°C with allowed excursions, and a note to keep out of reach of children. The label shows a package size of 30 tablets and is distributed by Cytokinetics Inc., South San Francisco, CA. The label also displays a barcode, lot number, expiration date, serial number, and GTIN.*

FDA Label Image

Principal Display Panel (15 mg Tablet Bottle Label)

MYQORZO 15 mg (aficamten) film-coated tablets label showing the strength of 15 mg. The label includes storage instructions, barcode, batch lot number, expiration date placeholder, serial number, and GTIN. It states the medication guide attachment, prescription-only status, 30 tablets per container, and distributor information for Cytokinetics Inc., South San Francisco, CA.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Label for MYQORZO (aficamten) tablets, 20 mg strength. The label includes dosing and storage instructions, a lot number, expiration date placeholder, serial number, and GTIN. It specifies the product as prescription only with 30 tablets per package. Distributed by Cytokinetics Inc., South San Francisco, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.